Pranoprofen

SKU: orb1310884

Description

Pranoprofen, also known as Pyranoprofen, is a non-steroidal anti-inflammatory drug (NSAID) primarily applied in ophthalmic research. It is utilized in both in vitro and in vivo studies to investigate its mechanisms in reducing ocular inflammation and pain, serving as a key compound in pharmacological and ophthalmological research fields.

Research Area

Cell Biology, Immunology & Inflammation, Neuroscience, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 52549-17-4
• MW: 255.27
• Purity: 99.88% (May vary between batches)
• Formula: C₁₅H₁₃NO₃
• SMILES: CC(C(O)=O)c1ccc2Oc3ncccc3Cc2c1
• Target: Prostaglandin Receptor,COX,PGE Synthase,Apoptosis
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (7.83 mM);DMSO:50 mg/mL (195.87 mM);H2O:< 1 mg/mL (insoluble or slightly soluble);Ethanol:6 mg/mL (23.5 mM)

Bioactivity

• In Vivo:
  Pranoprofen is orally administered, urinary and fecal excretions of the radioactivity within 3 days are 81.1% and 18.7% of the dose in mice, 51.5% and 39.4% in rats, 81.8% and 9.0% in guinea pigs, and 93.2% and 3.6% in rabbits, respectively. Pranoprofen is excreted in the urine exclusively in the form of pranoprofen glucuronide in rabbit. Pranoprofen, especially the R(-)-isomer, is significantly distributed in the kidney of rabbit. Pranoprofen has a preference for glucosidation rather than glucuronidation in mice at low doses in spite of having a higher capacity of glucuronidation.
• In Vitro:
  Pranoprofen inhibits ER stress-induced glucose regulated protein 78 (GRP78) expression, an ER-localized molecular chaperon. Pranoprofen inhibits ER stress-induced CCAAT/enhancer-binding protein homologous protein (CHOP) expression, an apoptotic transcription factor. Pranoprofen alone induces eIF2alpha phosphorylation, which is further increased by ER stress. Pranoprofen inhibits ER stress-induced X-box-binding protein 1 (XBP-1) splicing in the primary cultured glial cells. Pranoprofen (0.0625 to 1.0 g/L) has poignant cytotoxicity to human corneal endothelial (HCE) cells, and the extent of its cytotoxicity is dose- and time-dependent. Pranoprofen induces plasma membrane permeability elevation, DNA fragmentation, and apoptotic body formation, proving its apoptosis inducing effect on HCE cells. Pranoprofen above 0.0625 g/L has poignant cytotoxicity on HCE cells in vitro by inducing cell apoptosis, and should be carefully employed in eye clinic.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Apoptosis, COX, colon cancer, Cyclooxygenase, disease, ophthalmology, Pyranoprofen, inhibit, keratitis, NSAID, pain, ER stress, Inhibitor, Prostaglandin Receptor, ProstaglandinReceptor, Prostaglandin E synthase, prostaglandin, PGE2, PGE synthase, PGE Synthase, Pranoprofen, PGESynthase

Compound Identifiers

PubChem CID

4888